secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2024-04-09T23:59:59+00:00
Accession:  0000950103-24-005064
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics presents exatecan-based ADC platform at virtual investor event
-------------------------------------------------------------------------------

- CEO Ameet Mallik and CSO Patrick van Berkel to present updates on novel exatecan-based ADC platform.
- Agenda includes business update, research strategy, platform, and lead candidates.
- Presentation made available on April 9, 2024, with live Q&A session to follow.
- No financial results or material non-public information disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000095010324005064/0000950103-24-005064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000095010324005064/dp209553_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-24-005064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer